C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
12/2006
12/14/2006	US20060281138 Methods for diagnosis of low grade astrocytoma
12/14/2006	US20060281131 Monoclonal antibodies; renal diseases; kits
12/14/2006	US20060281130 Metod of modulation of interaction between receptor and ligand
12/14/2006	US20060281125 ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
12/14/2006	US20060281111 isolated polyclonal antibody of given sequence; use in detecting, diagnosing, staging or monitoring progression of cancer, inflammatory, autoimmune, cardiovascular, and neurological disorders
12/14/2006	US20060281095 44 human secreted proteins
12/14/2006	US20060281089 Detecting presence of mutant bcl gene of given sequence; identifying patients resistant to chemotherapy or radiation treatments
12/14/2006	US20060281081 Method of diagnosing colon and gastric cancers
12/14/2006	US20060281080 Novel lipases and uses thereof
12/14/2006	US20060281078 Human fast-1 gene
12/14/2006	US20060281072 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy
12/14/2006	US20060280759 Live and subunit vaccines
12/14/2006	US20060280751 Method for enhancing efficacy of preparation of monoclonal antibody
12/14/2006	US20060280750 Anti-idiotypic antibodies which recognise the idiotope of an antibody specific for a yeast killer toxin possess microbicidal activity
12/14/2006	US20060280749 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
12/14/2006	US20060280747 capable of binding to mouse Vascular endothelial cell growth factor (VEGF) and human VEGF; cancer, diabetes related diseases, edema, inflammation
12/14/2006	US20060280745 Prion inhibition
12/14/2006	US20060280743 Immunoglobulin for treatment of alzheimer's diseases
12/14/2006	US20060280742 monoclonal antibody for treating cancer, neovascularization, vascular and arthritic diseases; immunoassay; immunotherapy; inhibition or antagonism of TNF decreases expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF); decrease angiogenesis
12/14/2006	US20060280741 Administering the antibody concurrently with an antagonist of IL-1 alpha to treat psoriatic arthritis; arthritis nodosa; seronegative spondylarthropathy, and ulcerative colitis
12/14/2006	US20060280740 Compositions and methods for regulating NK cell activity
12/14/2006	US20060280739 Novel human beta-2 integrin alpha subunit
12/14/2006	US20060280737 Reducing body weight or food intake ; binding to antibody
12/14/2006	US20060280736 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/14/2006	US20060280735 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/14/2006	US20060280734 Retargeting
12/14/2006	US20060280733 Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
12/14/2006	US20060280732 To suppress apoptotic pathways by inhibiting cytochrome c-mediated caspase activation; inhibit effects of apoptosis induced by oxidative stress, drugs, cytokines, Fas-ligand, alpha-fetoprotein, used to prevent apoptosis in culturing cells, in organ transplantation, in immunological autoimmune disorder
12/14/2006	US20060280727 Dendritic cell isolation methods
12/14/2006	US20060280688 noninvasive imaging in near-infrared (NIR) spectral range for tumor detection with a ligand-conjugated fluorescent probe
12/14/2006	US20060280684 Using lymphocyte gene expression profiles as diagnostic indicator of asthma, allergic and autoimmune disorders
12/14/2006	US20060280679 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
12/14/2006	DE202006007590U1 Use of agent that inhibits interaction between Sema7A and VLA-1 for treatment or prevention of cytokine-mediated diseases, e.g. osteoarthritis and arteriosclerosis
12/14/2006	CA2611861A1 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
12/14/2006	CA2611433A1 Novel analgesic treatment with prolonged effect using an anti-trka antibody
12/14/2006	CA2610771A1 Anti-trkb monoclonal antibodies and uses thereof
12/14/2006	CA2610685A1 Methods of treating, diagnosing or detecting cancer using an ephb3 modulator
12/14/2006	CA2610596A1 Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect
12/14/2006	CA2609999A1 Stable and soluble antibodies inhibiting tnfalpha
12/14/2006	CA2608818A1 Method of producing antibodies with modified fucosylation level
12/13/2006	EP1731907A1 Method of detecting allergen
12/13/2006	EP1731611A2 Eimeria hydrophilic polypeptides as vaccines
12/13/2006	EP1731605A1 Cancer antigen peptides derived from wt1
12/13/2006	EP1731531A2 Multiple cytokine-antibody complexes
12/13/2006	EP1731530A1 A kind of fusion protein, gene encoding it, expression method and use thereof
12/13/2006	EP1731171A1 Preventive/remedy for respiratory diseases
12/13/2006	EP1731168A1 Antibody drug
12/13/2006	EP1731166A2 Streptococcus pneumoniae proteins and vaccines
12/13/2006	EP1731161A1 Compositions for the treatment of diseases associated with elevated sphingolipid concentrations
12/13/2006	EP1731144A1 Identification of genes altered in multiple myeloma
12/13/2006	EP1731032A1 Nonhuman animals for antibody production, and methods and systems for producing antibodies using such animals
12/13/2006	EP1730525A1 Immunoassays for everolimus
12/13/2006	EP1730197A2 Methods for inducing autolysis in infectious bacteria
12/13/2006	EP1730196A2 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
12/13/2006	EP1730195A2 Estrogen receptors and methods of use
12/13/2006	EP1730194A2 Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof
12/13/2006	EP1730193A2 Monoclonal antibodies to gastrin hormone
12/13/2006	EP1730192A2 Compositions and methods for detecting cyclic analogs of human parathyroid hormone (hpth)
12/13/2006	EP1730191A2 Immunoglobulins
12/13/2006	EP1730190A2 Inhibiting cav3 isoforms and the &25b splice varients for the diagnosis and treatment of cancer
12/13/2006	EP1730185A1 Cancer associated antigens
12/13/2006	EP1730180A1 Antifungal peptides
12/13/2006	EP1729806A2 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
12/13/2006	EP1729805A2 Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts
12/13/2006	EP1729804A2 Reducing the risk of human and anti-human antibodies through v gene manipulation
12/13/2006	EP1729803A2 Therapeutic use of anti-cs1 antibodies
12/13/2006	EP1729799A2 Chemically programmable immunity
12/13/2006	EP1729780A2 Methods for protein production
12/13/2006	EP1729750A2 Method for inhibiting tumor formation and growth
12/13/2006	EP1615670A4 Targets for tumor growth inhibition
12/13/2006	EP1613656B1 Cancerous disease modifying antibodies
12/13/2006	EP1534836B1 Mutant forms of meningococcal adp-ribosylating toxin
12/13/2006	EP1482975B1 Prevention of tissue adhesion
12/13/2006	EP1268836B1 Non-human sperm-dna complexes for genetically modifying non-human animals
12/13/2006	EP1261712B1 Proteins named fctrx and nucleic acids encoding same
12/13/2006	EP1179067B1 Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily
12/13/2006	EP1171605B1 Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof
12/13/2006	EP1123392B1 Prv-1 gene and the use thereof
12/13/2006	EP1121151B1 Anti-inflammatory alpha2, beta1 integrin-related substances or antibodies
12/13/2006	EP1117803B1 Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus
12/13/2006	EP1108786B1 Novel collectin
12/13/2006	EP1078078B1 Complex formed by a peptide and a major histocompatibility complex at the surface of phages
12/13/2006	EP0991662B1 Chlamyidia trachomatis specific peptides and their use in diagnostic assays
12/13/2006	EP0980429B1 Human toll-like receptor proteins, related reagents and methods
12/13/2006	EP0973914B1 Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
12/13/2006	EP0854885B1 Recombinant anti-cd4 antibodies for human therapy
12/13/2006	EP0809695B1 Transcription factor - e2f-5
12/13/2006	EP0760602B1 Use of fas ligand to suppress lymphocyte-mediated immune responses
12/13/2006	EP0651805B1 Method of intracellular binding of target molecules
12/13/2006	CN1878871A IL-1 receptor based antagonists and methods of making and using
12/13/2006	CN1878795A Antibodies directed to phospholipase A2 and uses thereof
12/13/2006	CN1878794A NGF antagonist and opioid analgesic use in pain treatment
12/13/2006	CN1878793A Monoclonal antibodies against HMGB1
12/13/2006	CN1878792A Nogo-a binding molecules and pharmaceutical uses therof
12/13/2006	CN1878790A Neutralizable epitope of HGF and neutralizing antibody binding to the same
12/13/2006	CN1878568A Enhanced B cell cytotoxicity of CDIM binding antibody
12/13/2006	CN1878562A Antybody therapy
12/13/2006	CN1876683A Human antibodies that bind human TNFalpha
12/13/2006	CN1876679A Compounds from moraxella catarrhalis
12/13/2006	CN1289671C Antibody molecules having specificity for human tumor necrosis factory alpha, and use thereof

1 ... 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 ... 1494